Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013006813
pages 137-164

The Immune System in the Pathogenesis of Ovarian Cancer

Bridget Charbonneau
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Ellen L. Goode
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Kimberly R. Kalli
Division of Oncology, Mayo Clinic, Rochester, MN 55905
Keith L. Knutson
Department of Immunology, Mayo Clinic, Rochester, MN 55905
Melissa S. DeRycke
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905

RÉSUMÉ

Clinical outcomes in ovarian cancer are heterogeneous even when considering common features such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration into tumor and host characteristics. One compelling host characteristic is the immune response to ovarian cancer. While several studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease, recent genetic and protein analyses also suggest a role in disease incidence. Recent studies also show that anti-tumor immunity is often negated by immune suppressive cells present in the tumor microenvironment. These suppressive immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, future research into immunotherapy targeting ovarian cancer will likely become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression or by disrupting critical cytokine networks.


Articles with similar content:

CD40 and Dendritic Cell Function
Critical Reviews™ in Immunology, Vol.23, 2003, issue 1-2
Ranjeny Thomas, Brendan O'Sullivan
Gene Expression in Stem Cells
Critical Reviews™ in Eukaryotic Gene Expression, Vol.19, 2009, issue 4
Yu Liang, Criss Walworth, Iain Russell, Caifu Chen
Peptide Mimotopes as Prototypic Templates of Broad-Spectrum Surrogates of Carbohydrate Antigens for Cancer Vaccination
Critical Reviews™ in Immunology, Vol.27, 2007, issue 3
Gajendra Raghava, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi, Anastas Pashov
Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Keith L. Knutson, Douglas G. McNeel, Mary L. Disis, Donna Davis, Kathy Schiffman
Novel Functions of B Cells
Critical Reviews™ in Immunology, Vol.27, 2007, issue 2
Marilia Cascalho, Jeffrey L. Platt